Featured Research

from universities, journals, and other organizations

Alzheimer's Patients Are Dying Early Because Of Controversial Drugs

Date:
March 31, 2007
Source:
Alzheimer's Research Trust
Summary:
Many Alzheimer's patients are dying earlier because of sedatives they are being prescribed, according to new research from the Alzheimer's Research Trust. Results from a five-year project found that the drugs were linked with a significant increase in long-term mortality.

Rebecca Wood, Chief Executive of the Alzheimer's Research Trust.
Credit: Image courtesy of Alzheimer's Research Trust

Many Alzheimer’s patients are dying earlier because of sedatives they are being prescribed, according to new groundbreaking research from the Alzheimer's Research Trust.

Results from a five-year project, funded by the Alzheimer’s Research Trust and presented at the charity’s conference in Edinburgh, found that the drugs were linked with a significant increase in long-term mortality - with patients dying on average six months earlier.

The investigation by King’s College London researchers found that the sedatives, known as neuroleptics, were associated with a significant deterioration in verbal fluency and cognitive function, and that neuroleptic treatment had no benefit to patients with the mildest symptoms.

Significantly, up to 45% of people with Alzheimer’s disease residing in nursing homes are prescribed neuroleptics as a treatment for behavioural symptoms such as aggression.

Professor Clive Ballard, Professor of Age Related Disorders at King’s College London, and lead researcher on the project, said:

“It is very clear that even over a six month period of treatment, there is no benefit of neuroleptics in treating the behaviour in people with Alzheimer’s disease when the symptoms are mild – specifically when a measure of behavioural disturbance known as the Neuropsychiatric Inventory Score is equal to or less than 14. For people with more severe behavioural symptoms, balancing the potential benefits against increased mortality and other adverse events is more difficult, but this study provides an important evidence base to inform this decision-making process.”

Rebecca Wood, Chief Executive of the Alzheimer’s Research Trust, said:

“These results are deeply troubling and highlight the urgent need to develop better treatments. 700,000 people are affected by dementia in the UK, a figure that will double in the next 30 years. The Government needs to make Alzheimer’s research funding a priority.

“Only 11 is spent on UK research into Alzheimer's for every person affected by the disease, compared to 289 for cancer patients.”

Janet Carter, from West Yorkshire, whose parents were both diagnosed with Alzheimer’s, said: “My father died relatively quickly after he was diagnosed with Alzheimer’s and he was prescribed a neuroleptic drug. My mother, who also has Alzheimer’s, is still alive almost a decade after being diagnosed. She was never given these drugs. I don’t know if what happened to my dad is linked to these findings, but either way I’m very shocked by them.”

This is the largest neuroleptic withdrawal study of Alzheimer's patients and the only long-term one of its type.


Story Source:

The above story is based on materials provided by Alzheimer's Research Trust. Note: Materials may be edited for content and length.


Cite This Page:

Alzheimer's Research Trust. "Alzheimer's Patients Are Dying Early Because Of Controversial Drugs." ScienceDaily. ScienceDaily, 31 March 2007. <www.sciencedaily.com/releases/2007/03/070330230946.htm>.
Alzheimer's Research Trust. (2007, March 31). Alzheimer's Patients Are Dying Early Because Of Controversial Drugs. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2007/03/070330230946.htm
Alzheimer's Research Trust. "Alzheimer's Patients Are Dying Early Because Of Controversial Drugs." ScienceDaily. www.sciencedaily.com/releases/2007/03/070330230946.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins